To further elucidate transcriptional changes associated with sorafenib treatment, we measured the mRNA relative expression of Hypoxia Inducible factor-1 (HIF-1α), and found Significant increase in HIF-1α in HCC group to about 4-fold that of N group (p < 0.001), and further increased significantly in SF group (p < 0.001) indicating the occurrence of sorafenib resistance. The gene discussed is HIF1A; the disease is hepatocellular carcinoma.